Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT05031585
NCT05031585UnknownNot Applicable

A Pivotal, Double-blind, Parallel, Randomized, Multicenter, Superiority Clinical Trial to Evaluate the Efficacy and Safety of Nasal Lubricant Compared to Placebo on Snoring

Brainfarma Industria Química e Farmacêutica S/A1 site in 1 country90 target enrollmentStarted: February 18, 2022Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Not Applicable
Sponsor
Enrollment
90
Locations
1
Primary Endpoint
The effect of nasal lubricant in the improvement of snoring when compared to placebo.
Study OverviewStudy DesignEligibility CriteriaOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

Pivotal clinical trial, multicenter of superiority, randomized, double-blind, parallel groups, placebo-controlled and use of nasal lubricant on snoring.

Detailed Description

This study is designed for the improvement of snoring, characterized by a noise caused by the vibration of tissues obstructing the nasopharynx and oropharynx during sleep.

It is performed in participants of both sexes, over 18 years of age, who complain of snoring.

The rationale for studying the use of a medical device with nasal spray solution for snoring improvement is due to the fact that surface tension in the pharyngeal mucosa plays an important role in determining airway collapsibility.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Supportive Care
Masking
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Have signed the informed consent form;
  • •Participants of both genders aged ≥ 18 years;
  • •Report of snoring assessed objectively through the standardized criteria in the snoring noise domain in the Berlin questionnaire;

Exclusion Criteria

  • •History of allergy or hypersensitivity to the components of the nasal lubricant;
  • •Fixed nasal obstruction;
  • •Upper Airway Infections active or present for less than 7 days;
  • •Use of benzodiazepines and sleep inducing drugs;
  • •Under treatment for sleep apnea of any modality currently or within the past 6 months;
  • •Hepatic insufficiency;
  • •Active neoplastic disease;
  • •Severe sleep apnea determined by polysomnography (AHI > 30);
  • •Moderate sleep apnea with presence of excessive daytime sleepiness;
  • •Clinically significant illness or surgery, at the discretion of the principal investigator, within 30 days prior to study inclusion;
  • •History of chemical dependence or alcohol abuse;
  • •Any neurological and psychiatric disease or significant laboratory finding present, unless adequately controlled with medication allowed in the protocol;
  • •Patients with laboratory tests of SGOT, SGTP or CPK increased by at least two times the upper value of normal at the time of study inclusion;
  • •Women who are pregnant or breastfeeding or who have the desire to become pregnant;
  • •History of infarction and stroke;
  • •Craniofacial malformation;
  • •BMI > 35 Kg/m2;
  • •IDO ≥ 30 events/h determined in residence by Biologix®;
  • •Have symptoms of COVID-19 (fever, cold, loss of smell, loss of taste, dry cough, sore throat, diarrhea, difficulty breathing, fatigue, body aches and pains, headache).

Outcomes

Primary Outcomes

The effect of nasal lubricant in the improvement of snoring when compared to placebo.

Time Frame: 30 days of medical device use

For the primary endpoint, the level of continuous noise equivalent to the sound produced during sleep - LAeqT (equivalent-continuous sound pressure level), in dB(A), with a frequency filter in the weighting (sound level meter - Fusion SLM®) will be evaluated.

Secondary Outcomes

  • The effect of nasal lubricant on snoring reduction during polysomnography(30 days of medical device use)
  • The effect of nasal lubricant on snoring index, in residence using Biologix®.(Through study completion, an average of 30 days)
  • Perception of snoring reduction by the partner(30 days of medical device use)
  • The effect of nasal lubricant on apnea observed on polysomnography(30 days of medical device use)
  • The effect of nasal lubricant on sleep quality using the standardized daytime sleepiness assessment questionnaire(30 days of medical device use)
  • The effect of nasal lubricant on sleep quality using the standardized Sleep Apnea Quality Life Index (SAQLI) questionnaire(30 days of medical device use)
  • The effect of nasal lubricant on sleep quality using the Berlin Questionnaire / STOP-BANG Questionnaire(30 days of medical device use)
  • The effect of nasal lubricant on oximetry, in residence using Biologix®.(Through study completion, an average of 30 days)
  • Nasal lubricant on snoring reduction during polysomnography(30 days of medical device use)

Investigators

Sponsor
Brainfarma Industria Química e Farmacêutica S/A
Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials

Completed
Phase 3
An Study of Efficacy and Safety of ClevudineChronic Hepatitis B
NCT01192854Eisai Co., Ltd.288
Active, not recruiting
Not Applicable
Microwave Treatment of Common and Plantar WartsWarts
NCT05371834Blackwell Device Consulting119
Recruiting
Phase 3
A Study to Investigate the Effect of DWP16001 as add-on Therapy to Drug A in Patients With Type 2 Diabetes MellitusType 2 Diabetes Mellitus
NCT05466643Daewoong Pharmaceutical Co. LTD.240
Terminated
Phase 3
A Comparative Study of FV-100 vs. Valacyclovir for the Prevention of Post-Herpetic NeuralgiaShinglesHerpes ZosterPostherpetic Neuralgia
NCT02412917ContraVir Pharmaceuticals, Inc.237
Suspended
Phase 3
Ketorolac Applied by Continuous IV Infusion for Treatment of Moderately Severe Postoperative Pain Following BunionectomyPain, Postoperative
NCT05324358Neumentum, Inc.341